Literature DB >> 21920893

Validity of an automated telephonic system to assess COPD exacerbation rates.

Erik W M A Bischoff1, Lonneke M Boer, Johan Molema, Reinier Akkermans, Chris van Weel, Jan H Vercoulen, Tjard R J Schermer.   

Abstract

Current tools for recording chronic obstructive pulmonary disease (COPD) exacerbations are limited and often lack validity testing. We assessed the validity of an automated telephonic exacerbation assessment system (TEXAS) and compared its outcomes with existing tools. Over 12 months, 86 COPD patients (22.1% females; mean age 66.5 yrs; mean post-bronchodilator forced expiratory volume in 1 s 53.4% predicted) were called once every 2 weeks by TEXAS to record changes in respiratory symptoms, unscheduled healthcare utilisation and use of respiratory medication. The responses to TEXAS were validated against exacerbation-related information collected by observations made by trained research assistants during home visits. No care assistance was provided in any way. Diagnostic test characteristics were estimated using commonly used definitions of exacerbation. Detection rates, compliance and patient preference were assessed, and compared with paper diary cards and medical record review. A total of 1,824 successful calls were recorded, of which 292 were verified by home visits (median four calls per patient, interquartile range three to five calls per patient). Independent of the exacerbation definition used, validity was high, with sensitivities and specificities between 66% and 98%. Detection rates and compliance differed extensively between the different tools, but were highest with TEXAS. Patient preference did not differ. TEXAS is a valid tool to assess COPD exacerbation rates in prospective clinical studies. Using different tools to record exacerbations strongly affects exacerbation occurrence rates.

Entities:  

Mesh:

Year:  2011        PMID: 21920893     DOI: 10.1183/09031936.00057811

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Features of a Mobile Support App for Patients With Chronic Obstructive Pulmonary Disease: Literature Review and Current Applications.

Authors:  Drishty D Sobnath; Nada Philip; Reem Kayyali; Shereen Nabhani-Gebara; Barbara Pierscionek; Anouk W Vaes; Martijn A Spruit; Evangelos Kaimakamis
Journal:  JMIR Mhealth Uhealth       Date:  2017-02-20       Impact factor: 4.773

2.  A Smart Mobile Health Tool Versus a Paper Action Plan to Support Self-Management of Chronic Obstructive Pulmonary Disease Exacerbations: Randomized Controlled Trial.

Authors:  Lonneke Boer; Erik Bischoff; Maarten van der Heijden; Peter Lucas; Reinier Akkermans; Jan Vercoulen; Yvonne Heijdra; Willem Assendelft; Tjard Schermer
Journal:  JMIR Mhealth Uhealth       Date:  2019-10-09       Impact factor: 4.773

3.  Aspiration and severe exacerbations in COPD: a prospective study.

Authors:  Lydia Cvejic; Nadine Guiney; Tiffany Nicholson; Kenneth K Lau; Paul Finlay; Kais Hamza; Christian Osadnik; Paul Leong; Martin MacDonald; Paul T King; Philip G Bardin
Journal:  ERJ Open Res       Date:  2021-01-25

4.  A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations.

Authors:  Takashi Motegi; Rupert C Jones; Takeo Ishii; Kumiko Hattori; Yuji Kusunoki; Ryuko Furutate; Kouich Yamada; Akihiko Gemma; Kozui Kida
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-05-31

5.  Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial.

Authors:  Erik W M A Bischoff; Reinier Akkermans; Jean Bourbeau; Chris van Weel; Jan H Vercoulen; Tjard R J Schermer
Journal:  BMJ       Date:  2012-11-28

6.  'Exacerbation-free time' to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease (COPD): a prospective observational study.

Authors:  L M Boer; E W Bischoff; X Borgijink; J H Vercoulen; R P Akkermans; H A M Kerstjens; W J Assendelft; T R Schermer
Journal:  NPJ Prim Care Respir Med       Date:  2018-04-03       Impact factor: 2.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.